• 대한중풍순환신경학회지
• /
• 제22권1호
• /
• pp.45-56
• /
• 2021

■ Background Heart Failure with Preserved Ejection Fraction(HFpEF) is a heart failure that appears to have normal contraction function. In the case of HFpEF, no pharmacological therapy has been found to improve clinical prognosis, so it should be approached as an symptomatic treatment, therefore alternatives are needed due to concerns over adverse effects such as electrolyte imbalance caused by medication. ■ Case report A 81 year old female patient with Heart Failure with Preserved Ejection Fraction(HFpEF) patient complained dyspnea. Herbal prescription Mokbanggi-tang and Oryeongsan was administered on 6th day and 8th day respectively since the symptoms started. The NYHA Classification and Chest X-ray had been evaluated during the treatment period. Until the 7th day, the patient was classified as Class II, and when discharged from the hospital on the 28th day, it gradually improved and was classified as Class II. Chest X-Ray took on 2nd day showed pleural effusion and it was aggravated until 13th day. Follow up Chest X-Ray showed improving state of pleural effusion from 20th day and gradually got better. Mokbanggi-tang treatment continued for 52 days and stopped on 58th day. After Mokbanggi-tang treatment ended, only Oryeongsan treatment was maintained. ■ Conclusion The present case report suggests that Korean-Western medicine approach with Mokbangki-tang and Oryeongsan might be effective to pleural effusion and heart failure symptoms such as poor physical activity shown in a NYHA Classification. This shows that Mokbanggi-tang and Oryeongsan can be a therapeutic option as a treatment for patient with Heart Failure with Preserved Ejection Fraction(HFpEF).

• 대한한방내과학회지
• /
• 제44권5호
• /
• pp.957-967
• /
• 2023

Background: According to Vaccine Adverse Events Reporting System data, generalized edema followed by the COVID-19 vaccine is uncommon, with only 333 reported cases, and of those, 224 (69%) are associated with the Pfizer-BioNTech vaccine. Case report: A 76-year-old male patient with heart failure with preserved ejection fraction presented with spontaneous generalized edema and otherwise normal cardiac exams following administration of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination that had lasted for approximately 60 days and was treated successfully using Korean medicine treatment. After the administration of Korean medicine treatment, the patient's symptoms in the bilateral limbs were dramatically controlled, without recurrence, for 2 months. As a result, generalized edema, which had been present for approximately 50 days, dramatically improved. Conclusion: This clinical case study suggests that a Korean medicine approach with Mokbangki-tang and Oryeong-san might be effective for the pleural effusion resolution of generalized edema after COVID-19 vaccination.

• Journal of Chest Surgery
• /
• 제37권9호
• /
• pp.755-761
• /
• 2004

말기 허혈성 심근질환에서 좌심실내 원형패취 성형술(Dor 술식)이 심근 기능의 개선에 미치는 영향을 알아보고자 서울대학교병원 흉부외과에서 시행한 Dor 술식의 결과를 분석해 보았다. 대상 및 방법： 1998년 4월부터 2002년 12월 사이에 좌심박출계수 35% 이하의 허혈성 심근질환으로 관상동맥우회술과 함께 Dor 술식을 시행한 45례의 환자를 대상으로 수술 전, 수술 직후 및 술 후 1년째에 심초음파, 심근 SPECT, 심도자 및 조영술을 시행하여 좌심실 박출계수 및 용적 등의 변화를 비교 분석하였다. 결과: 심폐바이패스 및 대동맥 차단시간은 각각 평균 141$\pm$64, 69$\pm$24분이었다. 7례에서 수술전에 대동맥내풍선펌프를 사용하였으며 수술 중 및 수술 후 저심박출 증후군을 보인 9례와 3례에서 대동맥내 풍선펌프를 삽입하였다. 수술 사망은 1례(2.2%)가 있었으며, 합병증으로는 저심박출 증후군(12례), 심방세동(5례), 급성신부전(4례), 출혈에 의한 재수술(4례) 등이 있었다. 술 후 1개월째 환자의 NYHA 기능지수는 평균 2.8에서 1.1로 유의하게 향상되었다(p < 0.01). 수술 직후 시행한 좌심실조영술상 박출계수는 수술 전과 비교해서 32 $\pm$ 9%에서 52$\pm$11%로, asynergy 분획은 57 $\pm$ 12%에서 22 $\pm$ 9%로, 좌심실확장기말, 수축기말 용적 계수들도 각각 125$\pm$39 mL/$m^2$, 85 $\pm$30 mL/$m^2$에서 66$\pm$23 mL/$m^2$, 32$\pm$16 mL/$m^2$으로 통계적으로 유의한 개선을 보였다(p<0.01). 술 후 1년째에 시행한 심초음파검사, 심근 SPECT, 심도자 및 조영술상 수술 직후와 비교해서 좌심박출계수, 좌심실 확장기말용적, 좌심실 수축기말용적은 큰 차이는 없었으나, 좌심실 용적들은 조금씩 늘어나는 양상을 보였다. 결론: 허혈성심근질환에서 좌심실내 패취 성형술은 현저하게 좌심박출계수의 향상과 좌심실용적의 감소를 가져오며 술 후 1년까지도 지속되었으나, 좌심실용적은 다소 증가하는 양상을 보여 술 후에도 좌심실의 재확장을 막기 위한 적극적인 약물치료가 필요함을 시사하였다.